Back to Journals » Therapeutics and Clinical Risk Management » Volume 2 » Issue 2

The return of fixed combinations in psychiatry: fluoxetine and olanzapine combination

Authors Richard C Shelton

Published 15 June 2006 Volume 2006:2(2) Pages 187—192

Richard C Shelton

 

Department of Psychiatry, Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, TN, USA

 

Abstract: Fixed combination psychotropics, such as a combination of a tricyclic and a typical antipsychotic, were widely prescribed a generation ago. These products were plagued by a number of problems, including serious side effects, which caused them to fall out of favor. More recently, a fixed combination of the atypical antipsychotic olanzapine and the serotonin selective reuptake inhibitor (SSRI) fluoxetine has been approved in the US for the treatment of bipolar I depression. Although the combination produced a robust clinical response relative to placebo or olanzapine alone, the response from practitioners has been mixed. The reasons for this are likely to be varied. Some practitioners who remember the earlier era of fixed combinations may simply be resistant to using products of this type. Moreover, the two constituents are available and many clinicians prescribe them independently. Finally, adverse events associated with olanzapine may make practitioners hesitant. For example, weight gain is a common side effect with olanzapine, and may be associated with hyperlipidemia or type II diabetes. Aggressive management of this problem appears to be helpful in preventing or reversing weight gain. It is not clear how weight gain is going to impact the uptake of this effective treatment.

 

Keywords: combination, atypical, antipsychotic, antidepressant, bipolar disorder, depression, weight

Download Article [PDF] 

Readers of this article also read:

Vinflunine in the treatment of bladder cancer

Mark Bachner, Maria De Santis

Therapeutics and Clinical Risk Management 2008, 4:1243-1253

Published Date: 5 December 2008

Treatment of severe psoriasis with infliximab

JA Leman, AD Burden

Therapeutics and Clinical Risk Management 2008, 4:1165-1175

Published Date: 5 December 2008

Silent myocardial infarction in women with type II diabetes mellitus and microalbuminuria

Elmir Omerovic, Gerhard Brohall, Markus Müller, Truls Råmunddal, Göran Matejka, et al

Therapeutics and Clinical Risk Management 2008, 4:705-711

Published Date: 8 August 2008

Hypokalemia secondary to capecitabine: a hidden toxicity?

Muhammad Wasif Saif, Mohammad Houman Fekrazad, Leslie Ledbetter, Robert B Diasio

Therapeutics and Clinical Risk Management 2007, 3:177-180

Published Date: 15 March 2007

Acne phototherapy with a 1450-nm diode laser: an open study

Natusko Konishi, Hideki Endo, Naoki Oiso, Shigeru Kawara, Akira Kawada

Therapeutics and Clinical Risk Management 2007, 3:205-209

Published Date: 15 March 2007